

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8156)

INSIDE INFORMATION
POSSIBLE DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS;
POSSIBLE POSTPONEMENT OF THE BOARD MEETING;
AND
POSSIBLE SUSPENSION OF TRADING

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Sinopharm Tech Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

POSSIBLE DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 30 JUNE 2024

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) that there may be a delay in publication of the Company’s annual results announcement for the year ended 30 June 2024 (the “**2024 Annual Results**”) due to the possible change of auditors of the Group. Based on the recent communication between Peng Sheng CPA Limited (“**Peng Sheng**”) and the Company, Peng Sheng may resign as auditors of the Group due to their available internal resources.

According to the articles of association of the Company, subject to compliance with the GEM Listing Rules, the Board may fill any casual vacancy in the office of the auditor of the Company. The Board is currently in the course of identifying a suitable replacement to fill the casual vacancy following the possible resignation of Peng Sheng. The Company will make further announcement in relation to the resignation of auditor and appointment of the new auditor as soon as practicable in accordance with the GEM Listing Rules.

Pursuant to Rule 18.49 of the GEM Listing Rules, the Company is required to publish the 2024 Annual Results not later than three months after the end of the financial year (i.e. on or before 30 September 2024). In light of the aforementioned circumstances, it is expected that the Company is unable to publish the 2024 Annual Results on or before 30 September 2024 as required by the GEM Listing Rules.

Though the delay in publication of the 2024 Annual Results would constitute non-compliance of Rule 18.49 of the GEM Listing Rules, the Board wishes to emphasise that the operations of the Group remain normal and the Company will use its best endeavour to publish the 2024 Annual Results to the Shareholders as soon as possible.

POSSIBLE POSTPONEMENT OF BOARD MEETING

The Board announces that due to the possible delay in publication of the 2024 Annual Results, the meeting of the Board (the “**Board Meeting**”) for the purpose of considering and approving, among others, the 2024 Annual Results will probably be postponed and the Company will publish further announcement to inform Shareholders on the date of the relevant Board Meeting as and when appropriate.

POSSIBLE SUSPENSION OF TRADING

Pursuant to Rule 17.49A of the GEM Listing Rules, the Stock Exchange will normally request suspension of trading in an issuer’s securities if an issuer fails to publish periodic financial information in accordance with the GEM Listing Rules, and the suspension will normally remain in force until the issuer publishes an announcement containing the requisite financial information.

The Board will make further announcement(s) as and when appropriate to inform the Shareholders of any updates in respect of (i) the date of the Board Meeting; (ii) the publication of the 2024 Annual Results; and (iii) the possible suspension of trading in the shares of the Company.

The Shareholders and potential investors should exercise caution when dealing in the

securities of the Company.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
HO Kam Kin
Executive Director

Hong Kong, 19 September 2024

As at the date of this announcement, the Board comprises Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Mr. HSU Dong An and Mr. HEUNG Pik Lun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at <https://www.hkexnews.hk> for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.